Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Irrisept Solution for Instrumented Spine Surgery

NCT: NCT06439953 · RECRUITING

NCT IDNCT06439953
StatusRECRUITING
Start Date2024-10-01
Completion2028-04
SponsorRhode Island Hospital (OTHER)
First posted
Last updated

Brief Summary

Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacteriocidal properties to eliminate hardware inoculation, thereby minimizing the risk of deep space infection, while obviating the risk of seroma development.

Frequently Asked Questions

What is Irrisept Solution for Instrumented Spine Surgery?

Irrisept Solution for Instrumented Spine Surgery is a clinical trial registered under NCT06439953. Current status: RECRUITING.

What is the status of NCT06439953?

The current status of NCT06439953 (Irrisept Solution for Instrumented Spine Surgery) is: RECRUITING.

When did Irrisept Solution for Instrumented Spine Surgery start?

Irrisept Solution for Instrumented Spine Surgery started on 2024-10-01.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.